2.4 Pharmacology of Stimulants, Cannabis, and Hallucinogens

2.4 Pharmacology of Stimulants, Cannabis, and Hallucinogens

Beyond CNS depressants and opioids, addiction counselors frequently encounter clients misusing psychostimulants, cannabis products, classic hallucinogens, and dissociative substances. Mastering the pharmacological mechanisms, toxicity profiles, withdrawal dynamics, and evidence-based treatment models for these substance classes is essential for clinical competence.

---

Stimulant Pharmacology: Cocaine vs. Methamphetamine

Central nervous system stimulants increase monoaminergic neurotransmission—specifically dopamine (DA), norepinephrine (NE), and serotonin (5-HT)—within the brain's mesolimbic and cortical pathways.

[Cocaine Mechanism]     --> Blocks Reuptake Transporters (DAT/NET/SERT)
[Methamphetamine Mech] --> Blocks Reuptake + Forces Release via VMAT2 Reversal

Pharmacological Mechanism Comparison

• Cocaine: A naturally derived plant alkaloid (Erythroxylum coca). It acts primarily as a competitive reuptake inhibitor of presynaptic monoamine transporters (DAT, NET, SERT), causing rapid accumulation of dopamine in the synaptic cleft. Cocaine also blocks voltage-gated sodium channels, giving it local anesthetic properties. Elimination half-life is brief (60 to 90 minutes).
• Methamphetamine: A synthetic amphetamine derivative. It possesses a dual mechanism: it blocks monoamine reuptake and reverses the action of vesicular monoamine transporter-2 (VMAT2), actively pumping dopamine out of storage vesicles directly into the presynaptic cytoplasm and synaptic cleft. Elimination half-life is prolonged (10 to 12 hours).

Chronic Toxicity and Methamphetamine Pathology

Chronic methamphetamine exposure produces profound neurotoxicity, destroying dopaminergic and serotonergic axon terminals in the striatum and cortex. Key clinical manifestations include:

• "Meth Mouth": Severe, rampant dental decay and tooth loss caused by drug-induced xerostomia (dry mouth), bruxism (teeth grinding), poor oral hygiene, and excessive consumption of sugary, acidic carbonated beverages.
• Formication ("Meth Bugs"): Tactile hallucinations of insects crawling under or on the skin, leading to compulsive skin picking and extensive excoriations/ulcerations.
• Methamphetamine Psychosis: Paranoia, auditory/visual hallucinations, and persecutory delusions that closely mimic paranoid schizophrenia.

---

Stimulant Withdrawal and Behavioral Interventions

Unlike opioids or alcohol, stimulant withdrawal does not present with life-threatening physical signs or seizures. However, it produces severe psychological distress:

• Withdrawal Features: Severe energy crash, profound anhedonia, intense depression, hypersomnia (or insomnia), hyperphagia (excessive appetite), psychomotor retardation or agitation, and overwhelming drug craving. Suicidal ideation during the crash phase represents the primary clinical emergency.
• Lack of Pharmacotherapy: There are currently NO FDA-approved medications for stimulant use disorders.

Gold-Standard Behavioral Treatments

Because pharmacotherapy is absent, evidence-based behavioral interventions represent the primary treatment standard:

---

Cannabis Pharmacology and Clinical Syndromes

Cannabinoid Neurobiology

Cannabis sativa contains over 100 cannabinoids, the primary psychoactive compound being Delta-9-Tetrahydrocannabinol (THC).

• Mechanism: THC acts as a partial agonist at Cannabinoid Type 1 (CB1) receptors located predominantly in the CNS (cerebral cortex, hippocampus, basal ganglia, cerebellum) and CB2 receptors in the peripheral immune system. CB1 activation inhibits presynaptic neurotransmitter release via retrograde endocannabinoid signaling.
• Clinical Acute Effects: Euphoria, relaxation, altered time perception, heightened sensory awareness, short-term memory impairment, impaired motor coordination, and hyperphagia ("munchies").

Cannabis Use Disorder and Hyperemesis Syndrome

• DSM-5-TR Cannabis Use Disorder: Characterized by persistent use despite social, occupational, or psychological impairment; tolerance; and a validated cannabis withdrawal syndrome (irritability, anxiety, sleep disturbances, vivid dreams, appetite loss, depressed mood, restlessness, abdominal pain, tremors).
• Cannabis Hyperemesis Syndrome (CHS): A paradoxical syndrome occurring in long-term, daily cannabis users characterized by severe, recurrent cycles of nausea, intractable vomiting, and abdominal pain. Pathognomonic Feature: Symptoms are temporarily relieved by compulsive hot baths or showers (which activate heat-sensitive TRPV1 receptors). The definitive treatment is complete, permanent cannabis cessation.

---

Hallucinogens and Dissociative Substances

Hallucinogenic substances are categorized into classic serotonergic hallucinogens, empathogens, and NMDA receptor antagonist dissociatives.

+-------------------------------------------------------------------------+
|                        HALLUCINOGENIC SUBSTANCES                        |
+-------------------------------------------------------------------------+
                                     |
       +-----------------------------+-----------------------------+
       |                             |                             |
       v                             v                             v
+--------------+              +--------------+              +--------------+
|   CLASSIC    |              |  EMPATHOGEN  |              | DISSOCIATIVE |
|  (LSD/Psil)  |              |   (MDMA)     |              | (PCP/Ketamine|
+--------------+              +--------------+              +--------------+
| 5-HT2A Agonist|             | 5-HT/DA Release|             | NMDA Blockade|
| Synesthesia  |              | Oxytocin Up  |              | Nystagmus    |
+--------------+              +--------------+              +--------------+

1. Classic Hallucinogens (LSD, Psilocybin, Mescaline, DMT)

• Mechanism: Potent agonists at postsynaptic 5-HT2A serotonin receptors in the prefrontal cortex.
• Effects: Visual perceptions/illusions, altered sense of time and space, and synesthesia (the transposition of sensory modalities, such as "seeing sounds" or "hearing colors").
• Safety Profile: Low physical toxicity and minimal physical dependence potential; primary risks are psychological ("bad trips", panic, acute psychosis) and Hallucinogen Persisting Perception Disorder (HPPD), characterized by distressing visual flashbacks long after use has ceased.

2. MDMA (Ecstasy / Molly)

• Mechanism: Causes massive vesicular release and reuptake inhibition of serotonin, dopamine, and norepinephrine, alongside oxytocin elevation.
• Effects: Acts as an empathogen/entactogen, increasing emotional closeness, empathy, euphoria, and sensory awareness.
• Clinical Risks: Severe, potentially fatal malignant hyperthermia, hyponatremia (caused by excessive water intake coupled with SIADH), serotonin syndrome, and post-use depression ("suicide Tuesday") due to acute serotonin depletion.

3. Dissociative Anesthetics (PCP, Ketamine)

• Mechanism: Non-competitive antagonists at glutamate NMDA receptors.
• Phencyclidine (PCP): Produces profound sensory dissociation, analgesia, blank stare, severe agitation, unpredictable violent outbursts, and characteristic vertical or rotational nystagmus.
• Ketamine: Used medically as an anesthetic and antidepressant; produces "k-hole" dissociation. Chronic misuse causes severe ulcerative cystitis ("ketamine bladder"), marked by dysuria, hematuria, and bladder wall fibrosis.